drugset / Trial / NCT01460381

A Study to Evaluate the Effect of Genotype on LY2216684

NCT01460381

Phase 1 Completed 18 enrolled Eli Lilly and Company
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study will evaluate how genetic profiles respond to LY2216684 and the effect of Quinidine on the pharmacokinetics (PK) of LY2216684 in a specific genetic profile. Side effects will be documented.

Timeline

Start
2011-10
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Quinidine Small molecule 300 mg Oral
Subject edivoxetine Small molecule 18 mg Oral